{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:50:04Z","timestamp":1790059804224,"version":"4.0.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite intensive treatment regimens, the outcome of Mycobacterium abscessus infections is extremely poor and thus novel treatment regimens are needed. Although tigecycline seems to be one of the best options currently available, its long-term use is hampered by severe toxic side effects as well as the need for intravenous administration and the relatively high concentrations required for efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the in vitro activity of omadacycline against M. abscessus and compare it with the activity of tigecycline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The concentration- and time-dependent killing capacities of omadacycline and tigecycline against M. abscessus subspecies abscessus were determined using a time\u2013kill kinetics assay. Time\u2013kill curves as well as concentration\u2013effect curves were generated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Time\u2013kill curves showed strong concentration-dependent antimicrobial activity for both omadacycline and tigecycline. Omadacycline showed inhibition of mycobacterial growth at 4\u2009mg\/L and mycobacterial killing at concentrations \u226516\u2009mg\/L. Tigecycline showed mycobacterial killing at concentrations \u22654\u2009mg\/L, achieving elimination at concentrations \u226516\u2009mg\/L. The concentration\u2013effect curves after 7\u2009days of exposure showed stasis, 1\u2009log mycobacterial killing and 2\u2009log mycobacterial killing at 3.3, 4.0 and 4.8\u2009mg\/L for omadacycline and 2.2, 2.7 and 3.4\u2009mg\/L for tigecycline, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this in vitro study on omadacycline activity, together with its favourable (pharmacokinetic) properties, suggest that omadacycline is a potential new agent for the treatment of M. abscessus infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz267","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T19:10:10Z","timestamp":1559329810000},"page":"2930-2933","source":"Crossref","is-referenced-by-count":74,"title":["Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus"],"prefix":"10.1093","volume":"74","author":[{"given":"Hannelore I","family":"Bax","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corn\u00e9 P","family":"de Vogel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W","family":"Mouton","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan E M","family":"de Steenwinkel","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"2020042614554796500_dkz267-B1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010\u20132014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"2020042614554796500_dkz267-B2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jcf.2015.09.007","article-title":"Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis","volume":"15","author":"Qvist","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2020042614554796500_dkz267-B3","doi-asserted-by":"crossref","first-page":"e02360","DOI":"10.1128\/AAC.02360-17","article-title":"The clarithromycin susceptibility genotype affects the treatment outcome of patients with Mycobacterium abscessus lung disease","volume":"62","author":"Guo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B4","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B5","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.03112-15","article-title":"Tigecycline is highly efficacious against Mycobacterium abscessus pulmonary disease","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/jac\/dku062","article-title":"Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections","volume":"69","author":"Wallace","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020042614554796500_dkz267-B7","doi-asserted-by":"crossref","first-page":"e02327-17","DOI":"10.1128\/AAC.02327-17","article-title":"Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe as part of the 2016 SENTRY Antimicrobial Surveillance Program","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042614554796500_dkz267-B9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042614554796500_dkz267-B10","volume-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes\u2014Second Edition: M24","year":"2011"},{"key":"2020042614554796500_dkz267-B11","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkq374","article-title":"Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis","volume":"65","author":"de Steenwinkel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020042614554796500_dkz267-B12","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/AAC.02864-15","article-title":"Tigecycline potentiates clarithromycin activity against Mycobacterium avium in vitro","volume":"60","author":"Bax","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AEM.14.2.170-177.1966","article-title":"Simplified, accurate method for antibiotic assay of clinical specimens","volume":"14","author":"Bennett","year":"1966","journal-title":"Appl Microbiol"},{"key":"2020042614554796500_dkz267-B14","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B15","doi-asserted-by":"crossref","first-page":"e00470-19","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B16","doi-asserted-by":"crossref","first-page":": e02522-18","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020042614554796500_dkz267-B17","article-title":"Omadacycline gastrointestinal effects\u2014an integrated safety analysis from the phase-3 ABSSSI and CABP studies","author":"Cornely","journal-title":"Abstracts of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/10\/2930\/33130038\/dkz267.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/10\/2930\/33130038\/dkz267.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T18:55:57Z","timestamp":1587927357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/10\/2930\/5522506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,6,24]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz267","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,24]]}}}